Apil patents expiration
1. Actonel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5583122 | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5583122 | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
|
US5583122 (Pediatric) | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Jun, 2014
(9 years ago) | |
| US6165513 | APIL | Film-coated tablet for improved upper gastrointestinal tract safety |
Jun, 2018
(5 years ago) | |
| US6432932 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US5994329 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6015801 | APIL | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6465443 | APIL | Method for inhibiting bone resorption |
Aug, 2018
(5 years ago) | |
|
US6165513 (Pediatric) | APIL | Film-coated tablet for improved upper gastrointestinal tract safety |
Dec, 2018
(5 years ago) | |
|
US6015801 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US5994329 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6432932 (Pediatric) | APIL | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6465443 (Pediatric) | APIL | Method for inhibiting bone resorption |
Feb, 2019
(5 years ago) | |
| US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
| US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
|
US7718634 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months ago) | |
|
US7192938 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 23, 2012 |
| Pediatric Exclusivity(PED) | Jan 23, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 14 April, 2000
Treatment: Method of treating paget's disease using actonel; 35 mg orally once a week for prevention of osteoporosis in postmenopausal women; 35 mg orally once a week for treatment of osteoporosis in postmenopau...
Dosage: TABLET;ORAL
ACTONEL family patents
2. Asacol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541170 | APIL | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US5541171 | APIL | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 January, 1992
Treatment: Treatment of ulcerative colitis
Dosage: TABLET, DELAYED RELEASE;ORAL
ASACOL family patents
3. Atelvia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5583122 | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5622721 | APIL | Dosage forms of risedronate |
Apr, 2014
(10 years ago) | |
|
US5583122 (Pediatric) | APIL | Pharmaceutical compositions containing geminal diphosphonates |
Jun, 2014
(9 years ago) | |
| US8246989 | APIL | Dosage forms of bisphosphonates |
Jan, 2026
(1 year, 8 months from now) | |
| US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(3 years from now) | |
| US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 08, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE;ORAL
ATELVIA family patents
4. Femcon Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ingredient
Market Authorisation Date: 14 November, 2003
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
FEMCON FE family patents
5. Femtrace patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6962908 | APIL | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Dec, 2021
(2 years ago) | |
| US7799771 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Dec, 2021
(2 years ago) | |
| US7572779 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Oct, 2025
(1 year, 5 months from now) | |
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 August, 2004
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
FEMTRACE family patents
6. Lo Loestrin Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 21, 2013 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
LO LOESTRIN FE family patents
7. Lo Minastrin Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(4 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET;ORAL
LO MINASTRIN FE family patents
8. Minastrin 24 Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 08, 2016 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 08 May, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
MINASTRIN 24 FE family patents
9. Norethindrone And Ethinyl Estradiol And Ferrous Fumarate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2013 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ingredient
Market Authorisation Date: 22 December, 2010
Treatment: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET, CHEWABLE;ORAL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE family patents
10. Taytulla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6652880 | APIL | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
Mar, 2020
(4 years ago) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: Prevention of pregnancy
Dosage: CAPSULE;ORAL
TAYTULLA family patents